IL1B and chronic myelogenous leukemia, BCR-ABL1 positive: Hence, IL-1β blockade shows promising therapeutic value in experimental models of MPN, chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia, and AML10,15–17.